Rivaroxaban and intracranial haemorrhage after mild traumatic brain injury: A dangerous combination?

Clinical Neurology and Neurosurgery

Volumn 136, Issue , 2015, Pages 73-78

  Beynon, Christopher ^a   Potzy, Anna ^a   Sakowitz, Oliver W ^a   Unterberg, Andreas W ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Anticoagulants; Factor Xa inhibitors; Haemostasis; Head injury; Intracerebral haemorrhage

Indexed keywords

PHENPROCOUMON; RIVAROXABAN; ANTITHROMBOCYTIC AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CRANIOTOMY; FEMALE; GLASGOW COMA SCALE; HUMAN; HYPERTENSION; INCIDENCE; INTERNATIONAL NORMALIZED RATIO; ISCHEMIC HEART DISEASE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MORTALITY; OUTCOME ASSESSMENT; PARTIAL THROMBOPLASTIN TIME; RETROSPECTIVE STUDY; SURVIVOR; TRAUMATIC BRAIN INJURY; BRAIN INJURIES; COMPLICATION; INTRACRANIAL HEMORRHAGE, TRAUMATIC; INTRACRANIAL HEMORRHAGES; MIDDLE AGED; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BRAIN INJURIES; FACTOR XA INHIBITORS; FEMALE; HUMANS; INTRACRANIAL HEMORRHAGE, TRAUMATIC; INTRACRANIAL HEMORRHAGES; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; RETROSPECTIVE STUDIES; RIVAROXABAN; TREATMENT OUTCOME;

EID: 84930965935     PISSN: 03038467     EISSN: 18726968     Source Type: Journal    
DOI: 10.1016/j.clineuro.2015.05.035     Document Type: Article

References (27)

1. M.R. Patel, K.W. Mahaffey, J. Garg, G. Pan, D.E. Singer, and W. Hacke Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N. Engl. J. Med. 365 2011 883 891 10.1056/NEJMoa1009638
2. J.C. Purrucker, D. Capper, L. Behrens, and R. Veltkamp Secondary hematoma expansion in intracerebral hemorrhage during rivaroxaban therapy Am. J. Emerg. Med. 2014 10.1016/j.ajem.2014.01.042
3. A. Maurice-Szamburski, T. Graillon, and N. Bruder Favorable outcome after a subdural hematoma treated with feiba in a 77-year-old patient treated by rivaroxaban J. Neurosurg. Anesthesiol. 26 2014 183 10.1097/ANA.0000000000000030
4. W. Pfeilschifter, S. Luger, R. Brunkhorst, E. Lindhoff-Last, and C. Foerch The gap between trial data and clinical practice - an analysis of case reports on bleeding complications occurring under dabigatran and rivaroxaban anticoagulation Cerebrovasc. Dis. 36 2013 115 119 10.1159/000352062
5. A. Karni, R. Holtzman, T. Bass, G. Zorman, L. Carter, and L. Rodriguez Traumatic head injury in the anticoagulated elderly patient: a lethal combination Am. Surg. 67 2001 1098 1100
6. A.S. Jagoda, J.J. Bazarian, J.J. Bruns Jr., S.V. Cantrill, A.D. Gean, and P.K. Howard Clinical policy: neuroimaging and decisionmaking in adult mild traumatic brain injury in the acute setting Ann. Emerg. Med. 52 2008 714 748 10.1016/j.annemergmed.2008.08.021
7. J.L. Mega, E. Braunwald, S.A. Murphy, A.N. Plotnikov, P. Burton, and R.G. Kiss Rivaroxaban in patients stabilized after a ST-segment elevation myocardial infarction: results from the ATLAS ACS-2-TIMI-51 trial (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction-51) J. Am. Coll. Cardiol. 61 2013 1853 1859 10.1016/j.jacc.2013.01.066
8. I. Melnikova The anticoagulants market Nat. Rev. Drug Discov. 8 2009 353 354 10.1038/nrd2851
9. J.P. Piccini, J. Garg, M.R. Patel, Y. Lokhnygina, S.G. Goodman, and R.C. Becker Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial Eur. Heart J. 2014 10.1093/eurheartj/ehu083
10. J. Beyer-Westendorf, K. Förster, S. Pannach, F. Ebertz, V. Gelbricht, and C. Thieme Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry Blood 124 2014 955 962 10.1182/blood-2014-03-563577
11. M. Molina, V.H. Hillard, and R. Fekete Intracranial hemorrhage in patient treated with rivaroxaban Hematol. Rep. 6 2014 5283 10.4081/hr.2014.5283
12. S.T. Garber, W. Sivakumar, and R.H. Schmidt Neurosurgical complications of direct thrombin inhibitors - catastrophic hemorrhage after mild traumatic brain injury in a patient receiving dabigatran J. Neurosurg. 116 2012 1093 1096 10.3171/2012.2.JNS112132
13. S.N. Wassef, T.J. Abel, A. Grossbach, S.V. Viljoen, A.W. Jackson, and M.A. Howard 3rd Traumatic intracranial hemorrhage in patients taking dabigatran: report of 3 cases and review of the literature Neurosurgery 73 2013 E368 E373 10.1227/01.neu.0000430763.95349.5f (discussion E373-E374)
14. M.W. Parra, L. Zucker, E.S. Johnson, D. Gullett, C. Avila, and Z.A. Wichner Dabigatran bleed risk with closed head injuries: are we prepared? J. Neurosurg. 119 2013 760 765 10.3171/2013.3.JNS12503
15. R. Berger, S.D. Salhanick, M. Chase, and M. Ganetsky Hemorrhagic complications in emergency department patients who are receiving dabigatran compared with warfarin Ann. Emerg. Med. 61 2013 475 479 10.1016/j.annemergmed.2013.02.008
16. M.M. Samama, G. Contant, T.E. Spiro, E. Perzborn, L. Le Flem, and C. Guinet Laboratory assessment of rivaroxaban: a review Thromb. J. 11 2013 11 10.1186/1477-9560-11-11
17. R. Bowry, S. Fraser, J.M. Archeval-Lao, S.A. Parker, C. Cai, and M.H. Rahbar Thrombelastography detects the anticoagulant effect of rivaroxaban in patients with stroke Stroke 45 2014 880 883 10.1161/STROKEAHA.113.004016
18. M. Kalina, G. Tinkoff, A. Gbadebo, P. Veneri, and G. Fulda A protocol for the rapid normalization of INR in trauma patients with intracranial hemorrhage on prescribed warfarin therapy Am. Surg. 74 2008 858 861
19. M. Edavettal, A. Rogers, F. Rogers, M. Horst, and W. Leng Prothrombin complex concentrate accelerates international normalized ratio reversal and diminishes the extension of intracranial hemorrhage in geriatric trauma patients Am. Surg. 80 2014 372 376
20. C.H. Woo, N. Patel, C. Conell, V.A. Rao, B.S. Faigeles, and M.C. Patel Rapid warfarin reversal in the setting of intracranial hemorrhage: a comparison of plasma, recombinant activated factor VII, and prothrombin complex concentrate World Neurosurg. 2012 10.1016/j.wneu.2012.12.002
21. D.R. Spahn, B. Bouillon, V. Cerny, T.J. Coats, J. Duranteau, and E. Fernández-Mondéjar Management of bleeding and coagulopathy following major trauma: an updated European guideline Crit. Care 17 2013 R76 10.1186/cc12685
22. R. Marlu, E. Hodaj, A. Paris, P. Albaladejo, J.L. Cracowski, and J.L. Crackowski Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers Thromb. Haemost. 108 2012 217 224 10.1160/TH12-03-0179
23. F.M.H. Lee, A.K.C. Chan, K.K. Lau, and H.H. Chan Reversal of new, factor-specific oral anticoagulants by rFVIIa, prothrombin complex concentrate and activated prothrombin complex concentrate: a review of animal and human studies Thromb. Res. 133 2014 705 713 10.1016/j.thromres.2014.01.031
24. F. Akwaa, and A.C. Spyropoulos Treatment of bleeding complications when using oral anticoagulants for prevention of strokes Curr. Treat. Options Cardiovasc. Med. 15 2013 288 298 10.1007/s11936-013-0238-5
25. A. Fawole, H.A. Daw, and M.A. Crowther Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban Clevel. Clin. J. Med. 80 2013 443 451 10.3949/ccjm.80a.13025
26. J. Stangier, K. Rathgen, H. Stähle, and D. Mazur Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study Clin. Pharmacokinet. 49 2010 259 268 10.2165/11318170-000000000-00000
27. G. Lu, F.R. DeGuzman, S.J. Hollenbach, M.J. Karbarz, K. Abe, and G. Lee A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa Nat. Med. 19 2013 446 451 10.1038/nm.3102